Get the Daily Brief
Latest Biotech News
FDA approval – PV treatment license/branding
Takeda’s Mimrylo (rusfertide) won U.S. FDA clearance for adults with polycythemia vera, a rare blood cancer marked by excessive red blood cell production. The therapy is a weekly injectable...
Clinical/Regulatory development – silencing vs stabilizers in ATTR-CM
AstraZeneca reported trial failure for Wainua in transthyretin amyloid cardiomyopathy (ATTR-CM), renewing debate about whether RNA-silencing approaches deliver incremental benefit when patients...
Oncology discovery – immune-oncology target with sex-biased macrophage crosstalk
Researchers reported a pan-cancer single-cell atlas that links therapy resistance and immunotherapy response differences to sex-biased SPP1+ macrophage crosstalk with tumor cells. The study...
Clinical signal – durvalumab plus T-DXd for HER2-low metastatic breast cancer
The BEGONIA platform trial reported unusually deep and durable tumor responses from combining the HER2-directed antibody-drug conjugate trastuzumab deruxtecan with durvalumab and trastuzumab in a...
AI for precision medicine – multimodal foundation model using EHR plus genomics
Verily Health, working with NVIDIA and the NIH All of Us Research Program, developed an early multimodal foundation model that integrates electronic health records and genomic data—an effort...
AI in diagnostics – explainable modeling for disability trajectories in hospitalized older adults
A research team in China developed an explainable AI model intended to forecast disability trajectories for hospitalized older adults with chronic back pain, aiming to provide predictions while...
Radiopharmaceuticals – expert push for more frequent dosing
Radiopharmaceutical leaders argued that the oncology sector is not fully leveraging the field’s dosing potential, citing a pattern of safety limitations that have constrained how often...
Diabetes prevention – GLP-1 class review in prediabetes
A review in Diabetes Therapy concluded that GLP-1 receptor agonists—including liraglutide and semaglutide—along with the dual-acting drug tirzepatide, show promise in stopping type 2 diabetes from...
Company licensing/partnership – late-stage epilepsy asset moves to SK Bio
Biohaven outlicensed global rights to opakalim, a Kv7-targeting small molecule in pivotal epilepsy testing, to SK Biopharmaceuticals while receiving non-dilutive financing for its pipeline. The...
Regulatory approval: prostate/adult PV
FDA cleared Takeda’s hepcidin mimetic Mimrylo (rusfertide) for adults with polycythemia vera (PV), following late-phase evidence demonstrating the therapy’s ability to address erythrocytosis in...
FDA approval: oral RAS(ON) inhibitor for metastatic pancreatic cancer
The FDA approved Revolution Medicines’ oral RAS(ON) inhibitor Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma in patients who received at least one prior systemic therapy or are...
Clinical-stage oncology: durvalumab plus trastuzumab deruxtecan in HER2-low breast cancer
BEGONIA, a phase 1b/2 platform trial, reported durable responses by pairing durvalumab with trastuzumab deruxtecan in women with HER2-low metastatic breast cancer. The study framework is designed...
Late-stage competition in cardiometabolic RNA therapy
Arrowhead said its RNA interference drug Redemplo showed a safety edge over Ionis Pharmaceuticals’ Wainua in the late-stage setting of ATTR-CM, intensifying focus on tolerability as efficacy...
Post-trial response: Alnylam defends RNAi heart disease strategy after AstraZeneca failure
After AstraZeneca disclosed Wainua’s failure in ATTR-CM, Alnylam moved to defend its RNAi “silencer” approach, arguing the clinical results do not negate the broader value proposition for its...
Clinical trial strategy: RNA-guided CAR-T accessibility via tumor vessel normalization
A small-molecule compound, erianin, was reported to normalize tumor vessels and improve access for CAR-T cells in a glioblastoma mouse model. The approach targets a key immunotherapy...
Hospital care delivery: digital outpatient support with an auditable hemocompatibility dashboard
A new “auditable hemocompatibility dashboard” was reported to turn guidance for HeartMate 3 management into a more reliable outpatient care workflow. The tool focuses on clots and bleeding...
Precision oncology immunotherapy signals: sex-biased macrophage crosstalk
A pan-cancer single-cell atlas reported that immunotherapy-relevant macrophage crosstalk varies by sex, identifying sex-biased SPP1+ macrophage interactions linked to how tumors respond to...
Regulatory and pipeline data feed: FDA Rasonque approval market reaction
A market-focused report revisited the FDA approval of Revolution Medicines’ oral pancreatic cancer therapy Rasonque (daraxonrasib) and how investors interpreted the move. Despite the Priority...
Biotech partnerships and licensing: SK Bio acquires US rights to opakalim
SK Biopharmaceuticals broadened its U.S. prospects by licensing Biohaven’s global rights (outside its retained territories) to opakalim, a Kv7-targeting small molecule in pivotal testing for...
Regulatory approvals and launches
The FDA cleared Takeda’s hepcidin mimetic Mimrylo (rusfertide) for adults with polycythemia vera, moving the therapy from the trial setting into routine U.S. care. Mimrylo is administered by...